Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Personalis Inc excels in Q4 earnings, eyes growth through strategic focus

Personalis Inc's Q4 2022 earnings call highlighted strong financial performance, strategic focus on MRD, and guidance for 2023 amidst market challenges and opportunities.
The company's strengths in partnerships, product innovation, and financial management position it well for future growth and success in a competitive landscape.
While facing challenges in sample delivery, margin expectations, and operational changes, Personalis Inc is poised to leverage opportunities in partnerships, product launches, and market expansion.
Navigating the evolving landscape with resilience and adaptability, Personalis Inc aims to drive growth, profitability, and innovation in the coming year.

Personalis Inc reports strong Q1 revenue growth and oncology progress

Personalis Inc's Q1 2023 performance showcased revenue growth and progress in oncology.
The company aims to launch NeXT Personal for clinical use by Q4 2023, targeting cancer diagnostics.
Challenges include managing expenses, net loss, and ensuring efficient cash usage for financial goals.

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Personalis, Inc. (NASDAQ:PSNL ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Vivian Bais - BTIG Joseph Conway - Needham Arthur He - H.C. Wainwright Operator Good day, ladies and gentlemen and welcome to the Personalis Third Quarter 2022 Earnings Conference Call.

Personalis, Inc. (PSNL) Q3 2022 Earnings Call Transcript

Personalis (PSNL) delivered earnings and revenue surprises of 7.94% and 5.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates

Personalis Reports Third Quarter 2022 Financial Results

Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business

Personalis to Announce Third Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer. Specifically, the collaboration will focus on identifying composite biomarkers—those that integrate multiple biological entities into a single readout—to help guide therapeutic decision making. Gastroesophageal cancer is the fourth most common cancer worldwide, with

Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Personalis Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to

Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis' growing intellectual property portfolio relating to detection of molecular residual disease (MRD). The patent, US Patent No. 11,408,033 (the “‘033 patent”), which issued on August 9, 2022, claims priority to one of Personalis' earliest pat

Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics

MENLO PARK, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Personalis in partnership with BC Cancer to assess clinical and economic benefits of ctDNA for colorectal and pancreatic cancers

Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers

ARK Innovation ETF

Exact Sciences

Markforged Holding Corp

Pacific Biosciences of California

Teladoc

Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.

5 Top Stocks Cathie Wood Bought This Week

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022. About Personalis Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evo

Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Personalis, Inc. (NASDAQ:PSNL ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President & Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Participants Stephanie Iannetta - Cowen Joseph Conway - Needham & Company Mark Massaro - BTIG Derik De Bruin - Bank of America Arthur He - H.C. Wainwright & Company.

Personalis, Inc. (PSNL) CEO John West on Q2 2022 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022. Second Quarter and Recent Highlights Reported quarterly revenue of $18.2 million in the second quarter of 2022 compared with $21.7 million in the second quarter of 2021 Revenue from biopharma and other customers, excluding the VA MVP (as defined below), of $14.2 million in the second quarter of 20

Personalis Reports Second Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis' U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis' intellectual property portfolio in the field of whole genome-enabled, tumor-informed molecular residual disease (MRD) testing. Personalis' patent portfolio protects its pioneering work

Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance

Personalis to Announce Second Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013. US Patent No. 11,384,394 describes the detection of MRD and recurrence by using whole genome sequencing of a patient's tumor to identify variants for a personalized liquid biopsy assay. As with recently issued US Patent 11,299,783, the ‘394 patent covers many el

Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease

Today, we profile Personalis, a small cancer genomics testing firm. The stock has taken a battering in 2022 and is posting substantial quarterly losses, but shares now sell for less than net cash.

The Prognosis For Personalis

Personalis, Inc. (NASDAQ:PSNL ) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President and CEO Aaron Tachibana - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Max Masucci - Cowen Mark Massaro - BTIG Mike Matson - Needham & Co. Kevin DeGeeter - Oppenheimer Sean Lee - H.C. Wainwright Operator Good day, ladies and gentlemen.

Personalis, Inc.'s (PSNL) CEO John West on Q1 2022 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Reported quarterly revenue of $15.2 million in the first quarter of 2022 compared with $20.9 million in the first quarter of 2021 Revenue from biopharma and other customers, excluding the VA MVP (as defined below), of $11.7 million in the first quarter of 2022 c

Personalis Reports First Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following investor conferences: Bank of America 2022 Healthcare Conference Presenting on Wednesday, May 11, 2022 at 6:20 p.m. Eastern Time at the Encore Hotel in Las Vegas A live audio webcast and replay of the presentation may be accessed for 90 days on the “Investors” section of the company's website at: https://personalis

Personalis to Present at Upcoming Investor Conferences

Evaxion Biotech A/S

MENLO PARK, Calif. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion's personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion's proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with

Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the company's objective to accelerate expansion into the clinical market. “We are excited to welcome James to the team as he brings more than 20 years of successful commercial experience in oncology molecular diagnostics,” said John

Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (866) 220-806

Personalis to Announce First Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, "A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity," in Nature Communications. Human leukocyte antigen loss of heterozygosity (HLA LOH) allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presen

News for Personalis Inc Stock (PSNL)